Ceftaroline Dosage

Medically reviewed by Drugs.com. Last updated on Mar 25, 2024.

Usual Adult Dose for Pneumonia

600 mg IV every 12 hours

Duration of therapy:

• Acute bacterial skin and skin structure infections (ABSSSI): 5 to 14 days
• Community-acquired bacterial pneumonia (CABP): 5 to 7 days

Uses:

• For the treatment of ABSSSI due to susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, S agalactiae, Escherichia coli, Klebsiella pneumoniae, and K oxytoca
• For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), Haemophilus influenzae, K pneumoniae, K oxytoca, and E coli

Usual Adult Dose for Skin and Structure Infection

600 mg IV every 12 hours

Duration of therapy:

• Acute bacterial skin and skin structure infections (ABSSSI): 5 to 14 days
• Community-acquired bacterial pneumonia (CABP): 5 to 7 days

Uses:

• For the treatment of ABSSSI due to susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, S agalactiae, Escherichia coli, Klebsiella pneumoniae, and K oxytoca
• For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), Haemophilus influenzae, K pneumoniae, K oxytoca, and E coli

Usual Pediatric Dose for Skin and Structure Infection

Less than 2 months (gestational age at least 34 weeks and postnatal age at least 12 days): 6 mg/kg IV every 8 hours
2 months to less than 2 years: 8 mg/kg IV every 8 hours
2 years to less than 18 years (up to 33 kg): 12 mg/kg IV every 8 hours
2 years to less than 18 years (greater than 33 kg): 400 mg IV every 8 hours OR 600 mg IV every 12 hours

Duration of therapy: 5 to 14 days

Comments:

• Drug levels in cerebrospinal fluid have not been evaluated in pediatric patients younger than 2 months.
• No information available for dosing this drug in infants less than 34 weeks gestational age and younger than 12 days postnatal age.

Use: For the treatment of ABSSSI due to susceptible isolates of S aureus (including methicillin-susceptible and -resistant isolates), S pyogenes, S agalactiae, E coli, K pneumoniae, and K oxytoca

Usual Pediatric Dose for Pneumonia

2 months to less than 2 years: 8 mg/kg IV every 8 hours
2 years to less than 18 years (up to 33 kg): 12 mg/kg IV every 8 hours
2 years to less than 18 years (greater than 33 kg): 400 mg IV every 8 hours OR 600 mg IV every 12 hours

Duration of therapy: 5 to 14 days

Use: For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), H influenzae, K pneumoniae, K oxytoca, and E coli

Renal Dose Adjustments

Adults:

• Estimated CrCl greater than 50 mL/min: No adjustment recommended.
• Estimated CrCl greater than 30 to 50 mL/min: 400 mg IV every 12 hours
• Estimated CrCl 15 to 30 mL/min: 300 mg IV every 12 hours
• ESRD (CrCl less than 15 mL/min): 200 mg IV every 12 hours

Pediatrics:

• CrCl greater than 50 mL/min/1.73 m2: No adjustment recommended.
• CrCl less than 50 mL/min/1.73 m2: Data not available

Comments:

• Adults: CrCl estimated using the Cockcroft-Gault formula.
• Pediatrics: CrCl estimated using the Schwartz equation.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Known serious hypersensitivity to the active component or other cephalosporins

ABSSSI: Safety and efficacy have not been established in patients less than 34 weeks gestational age and younger than 12 days postnatal age.
CABP: Safety and efficacy have not been established in patients younger than 2 months.

Consult WARNINGS section for additional precautions.

Dialysis

Adults:

• Hemodialysis: 200 mg IV every 12 hours

Pediatrics: Data not available

Comments:

• Because this drug is hemodialyzable, it should be administered after hemodialysis on hemodialysis days.

Other Comments

Administration advice:

• Administer via IV infusion over 5 to 60 minutes in adults and pediatric patients at least 2 months of age; administer via IV infusion over 30 to 60 minutes in pediatric patients younger than 2 months.
• Therapy duration should be guided by severity and site of infection and by patient's clinical and bacteriological progress.

Storage requirements:

• Unreconstituted vials: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
• Constituted solution in Baxter Mini-Bag Plus: Store solutions (concentration range: 4 to 12 mg/mL) for up to 6 hours at room temperature or for up to 24 hours at 2C to 8C (36F to 46F).
• Constituted solution in infusion bag: Use within 6 hours when stored at room temperature or within 24 hours when stored at 2C to 8C (36F to 46F).

Reconstitution/preparation techniques:

• After constitution, further dilution is required; final volume for infusion into patients should be between 50 to 250 mL.
• The manufacturer product information should be consulted.

IV compatibility:

• Compatible: Sterile water for injection; 0.9% sodium chloride injection; 5% dextrose injection; 2.5% dextrose injection; 0.45% sodium chloride injection; lactated ringer's injection
• Compatibility with other drugs not established; should not mix with or physically add to solutions containing other drugs.

General:

• To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
• Appropriate specimens for microbiological testing recommended before therapy to isolate and identify infecting organisms and to establish susceptibility to this drug.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice:

• Avoid missing doses and complete the entire course of therapy.
• Contact healthcare provider if severe watery or bloody diarrhea occurs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer